A new report by Telix highlights the potential barriers to the adoption of innovative cancer treatments, specifically theranostics, in Australia. It warns that without government action to secure and regulate the nuclear medicine sector, many Australians could miss out on these advanced therapies. Theranostics combine diagnostics and treatment, using targeted radioactive isotopes for more accurate and safer cancer care. The report identifies regulatory issues, fragmented funding, and the lack of a clear pathway for radiopharmaceuticals as significant obstacles. Despite the promise of these treatments, current approvals are limited, and there is a need for more manufacturing capacity. A survey indicated strong public support for expanding Australia’s nuclear medicine industry and ensuring treatments are TGA-approved. Recommendations include enhancing regulatory oversight, streamlining funding, and establishing a $500 million Nuclear Medicines Fund to support research and manufacturing. Telix's CEO, Dr. Christian Behrenbruch, stressed the urgency for coordinated efforts to improve access to theranostics for Australian patients facing cancer.
Wed, 05 Mar 2025 22:40:20 GMT | Biotech Dispatch